Adenovirus Biology, Recombinant Adenovirus, and Adenovirus Usage in Gene Therapy.

Watanabe, Maki; Nishikawaji, Yuya; Kawakami, Hirotaka; Kosai, Ken-Ichiro

Watanabe, Maki; Nishikawaji, Yuya; Kawakami, Hirotaka; Kosai, Ken-Ichiro.

Afiliación

Watanabe M; Department of Gene Therapy and Regenerative Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima 890-8544, Japan.
Nishikawaji Y; Department of Gene Therapy and Regenerative Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima 890-8544, Japan.
Kawakami H; Department of Gene Therapy and Regenerative Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima 890-8544, Japan.
Kosai KI; Department of Gene Therapy and Regenerative Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima 890-8544, Japan.

Viruses ; 13(12)2021 12 14.

Article en En | MEDLINE | ID: mdl-34960772

Asunto(s)

Infecciones por Adenoviridae/virología; Adenoviridae/genética; Adenoviridae/fisiología; COVID-19/prevención & control; Terapia Genética; Animales; Vacunas contra la COVID-19; Línea Celular Tumoral; Expresión Génica; Vectores Genéticos; Humanos; Inmunoterapia; Virus Oncolíticos/genética; Células Madre Pluripotentes; Regiones Promotoras Genéticas; SARS-CoV-2; Survivin; Replicación Viral

Palabras clave

adenovirus; cancer immunotherapy; conditionally replicating adenovirus; cytokine; gene therapy; m-CRA; oncolytic virus; pluripotent stem cells; replication-defective adenoviral vector; survivin; vaccine

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Terapia Genética / Adenoviridae / Infecciones por Adenoviridae / COVID-19 Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Viruses Año: 2021 Tipo del documento: Article País de afiliación: Japón

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google